BNC Korea: 2025 Revenue KRW 95.9B, Operating Profit KRW 1.6B, New License Deal, No Buyback/Dividend

Consolidated 2025 revenue KRW 95.9B (+7.5% YoY), operating profit KRW 1.63B (-84.8%), net income KRW 2.05B (-84.6%)
Cash and cash equivalents KRW 99.2B, total assets KRW 278.0B, debt ratio 16.05%
Shareholder return: No dividend or share buyback/cancellation in 2025
In Jan 2026, signed license agreement with Leios Therapeutics for 10XB-101 (body fat reduction) in 8 countries including Korea and Taiwan
Major lawsuits: KRW 227M construction claim from Sejong industrial complex, criminal case for Pharmaceutical Affairs Act violation ongoing
Major shareholder Choi Wan-gyu holds 19.29%
R&D expenses KRW 5.14B (5.36% of revenue)